PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition and/or Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Chemotherapy Resistant Residual Triple Negative Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Neoplasm
Interventions: DRUG: AZD6738|DRUG: Olaparib|DRUG: Durvalumab
Sponsor: Institute of Cancer Research, United Kingdom
Collaborators: AstraZeneca